Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$9.75
$10.17
50-Day Range
N/A
52-Week Range
N/A
Volume
15,455 shs
Average Volume
39,077 shs
Market Capitalization
$158.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 1411th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elicio Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elicio Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.17% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 18.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.17% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 18.56%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

  • Read more about Elicio Therapeutics' insider trading history.
Receive ELTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELTX Stock News Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics: Q1 Earnings Snapshot
See More Headlines

ELTX Stock Analysis - Frequently Asked Questions

Elicio Therapeutics, Inc. (NASDAQ:ELTX) released its earnings results on Tuesday, May, 13th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.20.

Elicio Therapeutics (ELTX) raised $40 million in an initial public offering on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Top institutional shareholders of Elicio Therapeutics include Mayflower Financial Advisors LLC (0.06%).
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/13/2025
Today
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:ELTX
CIK
1555192
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$13.00
Potential Upside/Downside
+30.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-185.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.83
Quick Ratio
1.83

Sales & Book Value

Annual Sales
$2.30 million
Price / Sales
69.08
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.03) per share
Price / Book
-9.64

Miscellaneous

Outstanding Shares
16,000,000
Free Float
11,414,000
Market Cap
$158.88 million
Optionable
Not Optionable
Beta
1.18
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ELTX) was last updated on 8/5/2025 by MarketBeat.com Staff
From Our Partners